Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
CVS Health Corp.
CVS
NYSE·Healthcare·Medical - Healthcare Plans·Mkt cap $133.7B
$104.72
▼ -0.09%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$58.50 - $106.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 57.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Vertically integrated healthcare platform
- Extensive nationwide retail pharmacy network
- Comprehensive health insurance and pharmacy management services
- Strong brand recognition and consumer trust
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Telehealth and digital healthcare expansion
Value
Attractively priced below Managed Care & Health Insurance peer average
Momentum
Hot
+42.6% over 3m
Quality
Thin
Excellent business quality
Dividend
Solid
2.54% yield
Smart-money signal
Who's buying CVS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 6, 2026
Reported EPS of $2.57 vs $2.18 consensus (+17.9% surprise). Revenue of $100.4B vs $95.0B expected (+5.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+17.9%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+4%
+7%
+8%
+8%
+8%
+6%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$91.2B
$95.4B
$97.7B
$94.6B
$98.9B
$102.9B
$105.7B
$100.4B
Margins · last 8Q
Gross
15.6%
Operating
4.7%
Profit
2.9%
Wall Street consensus
15 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$106.00
▲ +1.2% vs $104.72
Latest: Bank of America · Jun 22, 2026
9 analysts covering